C
C. Birbara
Researcher at University of Massachusetts Medical School
Publications - 42
Citations - 6770
C. Birbara is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Placebo & Psoriatic arthritis. The author has an hindex of 21, co-authored 42 publications receiving 6425 citations. Previous affiliations of C. Birbara include University of Pennsylvania & University of Massachusetts Amherst.
Papers
More filters
Journal ArticleDOI
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Michael E. Weinblatt,Edward C. Keystone,Daniel E. Furst,Larry W. Moreland,Michael H. Weisman,C. Birbara,Leah A. Teoh,Steven A. Fischkoff,Elliot Chartash +8 more
TL;DR: The addition of adalimumab at a dosage of 20 mg, 40 mg, or 80 mg administered subcutaneously every other week to long-term MTX therapy in patients with active RA provided significant, rapid, and sustained improvement in disease activity over 24 weeks compared with MTX plus placebo.
Journal ArticleDOI
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
Mark C. Genovese,Jean-Claude Becker,Michael Schiff,Michael E. Luggen,Yvonne Sherrer,Joel M. Kremer,C. Birbara,Jane Box,Kannan Natarajan,Isaac Nuamah,Tracy Li,Richard Aranda,David Hagerty,Maxime Dougados +13 more
TL;DR: Abatacept produced significant clinical and functional benefits in patients who had had an inadequate response to anti-TNF-alpha therapy, including a clinically meaningful improvement in physical function.
Journal ArticleDOI
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni,Gerald G. Krueger,K. de Vlam,C. Birbara,A. Beutler,Cynthia Guzzo,B. Zhou,Lisa T. Dooley,Arthur Kavanaugh +8 more
TL;DR: Infliximab 5 mg/kg through 24 weeks significantly improved active PsA, including dactylitis and enthesopathy, and associated psoriasis.
Journal ArticleDOI
Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee
Nancy E Lane,Thomas J. Schnitzer,C. Birbara,Masoud Mokhtarani,David L. Shelton,Michael D. Smith,Mark T. Brown +6 more
TL;DR: Treatment with tanezumab was associated with a reduction in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee.
Journal Article
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Daniel E. Furst,Michael Schiff,Roy Fleischmann,Vibeke Strand,C. Birbara,Daniele Compagnone,Steven A. Fischkoff,Elliot Chartash +7 more
TL;DR: The data indicate that adalimumab is a safe and effective therapeutic option in patients with active RA who have an inadequate response to standard antirheumatic therapy, including one or more traditional DMARD, corticosteroids, NSAID, and analgesics.